The inflammatory orbitopathy associated with autoimmune thyroid disease is a major cause of ophthalmic disability. Thyroid eye disease (TED) can manifest with eyelid retraction, proptosis, orbital pain, diplopia, corneal exposure, and compressive optic neuropathy. Treatment traditionally falls into supportive care to address the exposure and pain, steroids to address acute inflammation, and extensive surgical reconstruction to address the anatomic manifestations that cause eyelid retraction, proptosis, and double vision.
We are excited to announce a forthcoming special topic issue in "Frontiers in Ophthalmology", specifically within the “Oculoplastics, Orbit, and Trauma” section, dedicated to exploring the multifaceted challenges and advances in the management of Thyroid Eye Disease (TED). This issue aims to delve into the comprehensive spectrum of TED, encompassing clinical and basic research, translational studies, innovative technologies, and cutting-edge surgical interventions. Our goal is to provide a platform for ophthalmologists, researchers, and clinicians to share pivotal findings and developments that can enhance understanding, diagnosis, and treatment of this complex condition.
To this end, we invite submissions of original research papers, review articles, case reports, and methodological advancements related to TED. Contributions may address, but are not limited to
• Pathophysiology
• molecular underpinnings
• novel diagnostic approaches
• medical management innovations
• surgical management techniques and strategies
• patient-centered care practices
• long-term outcomes.
We particularly encourage submissions that offer insights into innovative treatment modalities, use of new technologies in surgery, and integration of multidisciplinary care approaches. By compiling a diverse array of manuscripts, this special issue seeks to foster a deeper understanding of TED and propel forward the boundaries of what is possible in its management.
The inflammatory orbitopathy associated with autoimmune thyroid disease is a major cause of ophthalmic disability. Thyroid eye disease (TED) can manifest with eyelid retraction, proptosis, orbital pain, diplopia, corneal exposure, and compressive optic neuropathy. Treatment traditionally falls into supportive care to address the exposure and pain, steroids to address acute inflammation, and extensive surgical reconstruction to address the anatomic manifestations that cause eyelid retraction, proptosis, and double vision.
We are excited to announce a forthcoming special topic issue in "Frontiers in Ophthalmology", specifically within the “Oculoplastics, Orbit, and Trauma” section, dedicated to exploring the multifaceted challenges and advances in the management of Thyroid Eye Disease (TED). This issue aims to delve into the comprehensive spectrum of TED, encompassing clinical and basic research, translational studies, innovative technologies, and cutting-edge surgical interventions. Our goal is to provide a platform for ophthalmologists, researchers, and clinicians to share pivotal findings and developments that can enhance understanding, diagnosis, and treatment of this complex condition.
To this end, we invite submissions of original research papers, review articles, case reports, and methodological advancements related to TED. Contributions may address, but are not limited to
• Pathophysiology
• molecular underpinnings
• novel diagnostic approaches
• medical management innovations
• surgical management techniques and strategies
• patient-centered care practices
• long-term outcomes.
We particularly encourage submissions that offer insights into innovative treatment modalities, use of new technologies in surgery, and integration of multidisciplinary care approaches. By compiling a diverse array of manuscripts, this special issue seeks to foster a deeper understanding of TED and propel forward the boundaries of what is possible in its management.